UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

Journal of viral hepatitis, 2013-11, Vol.20 (11), p.745-760

2013

Volltextzugriff (PDF)

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

The New England journal of medicine, 2015-12, Vol.373 (27), p.2599-2607

2015

Volltextzugriff (PDF)

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

Journal of viral hepatitis, 2013-04, Vol.20 (4), p.e115-e123

2013

Volltextzugriff (PDF)

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (2), p.259-267

2018

Volltextzugriff (PDF)

Impact of common risk factors of fibrosis progression in chronic hepatitis C

Gut, 2015-10, Vol.64 (10), p.1605-1615

2015

Volltextzugriff (PDF)

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Journal of viral hepatitis, 2012-05, Vol.19 (s2), p.1-26

2012

Volltextzugriff (PDF)

Long-term clearance of hepatitis C virus following interferon [alpha]-2b or peginterferon [alpha]-2b, alone or in combination with ribavirin

Journal of viral hepatitis, 2013-08, Vol.20 (8), p.524

2013

Volltextzugriff (PDF)

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

Journal of viral hepatitis, 2013-08, Vol.20 (8), p.524-529

2013

Volltextzugriff (PDF)

Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

Journal of viral hepatitis, 2017-04, Vol.24 (4), p.280-286

2017

Volltextzugriff (PDF)

CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection

Clinical and experimental immunology, 2004-08, Vol.137 (2), p.408-416

2004

Volltextzugriff (PDF)

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

Journal of viral hepatitis, 2015-04, Vol.22 (4), p.366-375

2015

Volltextzugriff (PDF)

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

The New England journal of medicine, 1989-11, Vol.321 (22), p.1501

1989

Volltextzugriff (PDF)

Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190

Journal of viral hepatitis, 2016-08, Vol.23 (8), p.644-651

2016

Volltextzugriff (PDF)

Normal Functional Capacity in Circulating Myeloid and Plasmacytoid Dendritic Cells in Patients with Chronic Hepatitis C

The Journal of infectious diseases, 2005-08, Vol.192 (3), p.497-503

2005

Volltextzugriff (PDF)

Evaluation of the pattern of liver tests and yield of cholangiography in symptomatic choledocholithiasis: a prospective study

Gastrointestinal endoscopy, 1997-05, Vol.45 (5), p.394-399

1997

Volltextzugriff (PDF)

Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.554-555

2013

Volltextzugriff (PDF)

P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study

Gut, 2011-09, Vol.60 (Suppl 2), p.A32-A33

2011

Volltextzugriff (PDF)

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C

Journal of viral hepatitis, 2008-09, Vol.15 (9), p.623-633

2008

Volltextzugriff (PDF)

Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C

Brain, behavior, and immunity, 2005, Vol.19 (1), p.23-27

2005

Volltextzugriff (PDF)

Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations

Journal of viral hepatitis, 2012-04, Vol.19 (4), p.236-243

2012

Volltextzugriff (PDF)

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Journal of viral hepatitis, 2012-09, Vol.19 (9), p.623-634

2012

Volltextzugriff (PDF)

Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection

Journal of viral hepatitis, 2009-02, Vol.16 (2), p.141-148

2009

Volltextzugriff (PDF)

CD56+dim and CD56+bright cell activation and apoptosis in hepatitis C virus infection

Clinical and experimental immunology, 2004-08, Vol.137 (2), p.408-416

2004

Volltextzugriff (PDF)

P48 Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial

Gut, 2011-09, Vol.60 (Suppl 2), p.A23-A23

2011

Volltextzugriff (PDF)

Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile

Clinical therapeutics, 1994-03, Vol.16 (2), p.334-343

1994

Volltextzugriff (PDF)

1 – 25 von 16.039

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13.379)
Mit Volltextzugriff
(12.130)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(9.099)
Life Sciences & Biomedicine
(7.246)
Humans
(5.546)
Male
(3.211)
Female
(3.141)
Biological And Medical Sciences
(2.892)
Medical Sciences
(2.219)
Adult
(2.043)
Animals
(1.844)
Middle Aged
(1.828)
Physical Sciences
(1.326)
Aged
(1.131)
Technology
(980)
Fundamental And Applied Biological Sciences. Psychology
(886)
Adolescent
(871)
Infectious Diseases
(780)
Immunology
(729)
Child
(711)
Exact Sciences And Technology
(672)
General & Internal Medicine
(620)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(7.336)
Electronic Journals Library
(6.104)
Ingenta
(6.002)
Ovid Journals
(5.579)
Publisher website
(4.456)
Elsevier ScienceDirect Journals Complete
(3.362)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(2.218)
Wiley-Blackwell Full Collection
(2.032)
IngentaConnect Journals
(1.956)
Wiley Online Library Full Collection 2018
(1.321)
JSTOR
(1.014)
Springer Journals
(842)
Oxford Journals
(795)
Nexis Uni
(682)
Oxford Journals 2020 Medicine
(590)
Taylor & Francis Journals
(499)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(480)
Taylor & Francis
(456)
Taylor & Francis Journals Complete
(446)
Nature
(399)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

Impact of common risk factors of fibrosis progression in chronic hepatitis C

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Long-term clearance of hepatitis C virus following interferon [alpha]-2b or peginterferon [alpha]-2b, alone or in combination with ribavirin

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190

Normal Functional Capacity in Circulating Myeloid and Plasmacytoid Dendritic Cells in Patients with Chronic Hepatitis C

Evaluation of the pattern of liver tests and yield of cholangiography in symptomatic choledocholithiasis: a prospective study

Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply

P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C

Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C

Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection

CD56+dim and CD56+bright cell activation and apoptosis in hepatitis C virus infection

P48 Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial

Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile

Suchergebnisse filtern